Avid Bioservices Inc
NASDAQ:CDMO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.64
12.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Avid Bioservices Inc
Avid Bioservices Inc
Operating Income
Avid Bioservices Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avid Bioservices Inc
NASDAQ:CDMO
|
Operating Income
-$23m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-27%
|
CAGR 10-Years
6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$15.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$10.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$6.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Avid Bioservices Inc
Glance View
Avid Bioservices, Inc. engages in the commercial manufacturing. The company is headquartered in Tustin, California and currently employs 252 full-time employees. The firm is focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biopharmaceutical products derived from mammalian cell culture. The firm provides a range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. The Company’s services include CGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The firm also provides process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization.
See Also
What is Avid Bioservices Inc's Operating Income?
Operating Income
-23m
USD
Based on the financial report for Jul 31, 2024, Avid Bioservices Inc's Operating Income amounts to -23m USD.
What is Avid Bioservices Inc's Operating Income growth rate?
Operating Income CAGR 10Y
6%
Over the last year, the Operating Income growth was -1 686%.
You don't have any saved screeners yet
